This study demonstrated for the first time that ZnPP, as a novel sonosensitizer, could be used to treat tumors in SDT, to elucidate in detail the molecular mechanism of PEG-ZnPP-SDT in the treatment of ovarian cancer, and to prove that PEG-ZnPP-SDT could improve antitumor effects by destroying the HO-1 antioxidant system. Here, HMOX1 is linked to ovarian carcinoma.